Safety and Efficacy of Gardasil in Females With Juvenile Idiopathic Arthritis (JIA)/Seronegative Arthritis (CHASE)
Pilot Study of the Safety and Efficacy of Quadrivalent Human Papillomavirus Vaccine (Gardasil®) in Female Subjects With Juvenile Idiopathic Arthritis (JIA)/ Seronegative Arthritis
Sponsor: Merck Sharp & Dohme LLC
This NA trial investigates Arthritis and is currently completed. Merck Sharp & Dohme LLC leads this study, which shows 11 recorded versions since 2007 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
11 versions recorded-
Feb 2025 — Present [monthly]
Completed NA
-
Sep 2024 — Feb 2025 [monthly]
Completed NA
-
Aug 2024 — Sep 2024 [monthly]
Completed NA
Phase: PHASE4 → NA
-
Jul 2024 — Aug 2024 [monthly]
Completed PHASE4
-
Jun 2022 — Jul 2024 [monthly]
Completed PHASE4
▶ Show 6 earlier versions
-
Jan 2021 — Jun 2022 [monthly]
Completed PHASE4
Status: Unknown Status → Completed
-
Jul 2020 — Jan 2021 [monthly]
Unknown Status PHASE4
Status: Active Not Recruiting → Unknown Status
-
Jul 2018 — Jul 2020 [monthly]
Active Not Recruiting PHASE4
-
Jun 2018 — Jul 2018 [monthly]
Active Not Recruiting PHASE4
-
Mar 2018 — Jun 2018 [monthly]
Active Not Recruiting PHASE4
Status: Unknown Status → Active Not Recruiting
-
Jan 2017 — Mar 2018 [monthly]
Unknown Status PHASE4
First recorded
Nov 2007
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Merck Sharp & Dohme LLC
- MetroHealth System, Ohio
- The Cleveland Clinic
- University Hospitals Cleveland Medical Center
- University of Chicago
For direct contact, visit the study record on ClinicalTrials.gov .